Category

Blog

Discussions and articles surrounding trending topics in the liver industry

demonstration of FibroScan pulse when using probe

Battling liver disease

By All, Blog

Non-alcoholic fatty liver disease (NAFLD), affects approximately 100 million individuals in the United States. Its more serious form is called non-alcoholic steatohepatitis (NASH). NAFLD affects approximately 25% of the worldwide population and as many as 6% are affected by NASH, with NASH prevalence expected to increase by 63% by 2030.

Read More
Image of liver in yellow

FibroScan vs. Ultrasound Elastography

By All, Blog

A race is under way among pharmaceutical companies to develop drugs that treat a spectrum of liver diseases, including nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, and its more severe form, nonalcoholic steatohepatitis (NASH).

Read More
FibroScan Mini+ 430 with display on

Noninvasive Exams Can Help Head Off Liver Disease

By All, Blog

A race is under way among pharmaceutical companies to develop drugs that treat a spectrum of liver diseases, including nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, and its more severe form, nonalcoholic steatohepatitis (NASH).

Read More
Back and front views of FibroScan Mini+ 430

VA Tackles Liver Disease

By All, Blog

After reaching the goal of 100,000 veterans cured of hepatitis C virus (HCV) in as few as two months, the Department of Veterans Affairs (VA) now includes in its contract with Echosens the FibroScan® 430 mini+ portable technology.

Read More

November is National Diabetes Month

By All, Blog

Diabetes is one of the leading causes of disability and death in the United States. One in 10 Americans have diabetes — more than 30 million people — and another 84 million adults are at high risk of developing Type 2 diabetes.

Read More